Macanda welcomes Martina Kennedy as new Chief Executive Officer

Macanda is pleased to announce the appointment of Martina Kennedy as the company’s new Chief Executive Officer, effective October 7, 2025.

Martina is an experienced leader with broad life science experience who brings a strong understanding of innovative therapies and how to build great teams. Her appointment reflects Macanda’s commitment to develop a senior market access- and real-world evidence team with a deep scientific foundation that delivers lasting value for our clients and ultimately patients across the Nordics.

She succeeds Åsa By, who has served as interim CEO for the past year and will now return to her role as Senior Advisor and Partner, while continuing to support the company’s overall development as Chairman of the Board.

“I’m inspired by the opportunity to build and lead an organization of highly skilled professionals, where deep expertise and collaboration drive solutions to complex challenges,” says Martina Kennedy. “At Macanda, we have the chance to contribute to improving patient access to innovative treatments across the Nordics—a mission I find both purposeful and deeply motivating.”

Martina Kennedy brings over 20 years of leadership experience in the pharmaceutical and life sciences sector. She began her career at Pfizer and went on to spend more than a decade at Novartis Oncology, holding senior roles within Commercial, Market Access, External Affairs, and Franchise Leadership. Most recently, she led the Nordic Oncology Business Unit at Gilead Sciences and served as Interim Head of Nordic Market Access, where she also oversaw Virology and Established Products.

Martina is widely respected for her commercial acumen and her commitment to developing high-performing teams. Her deep expertise in market access, real-world evidence, and commercial leadership will be instrumental as Macanda continues to expand the quality, depth, and scope of its consulting services.